Lung Pathway Group – Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

Indication:
**NICE TA181**
First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma)

**Performance status 0 - 1**

**Regimen details:**
- **Pemetrexed**: 500 mg/m² IV Day 1
- **Cisplatin**: 75 mg/m² IV Day 1

**Administration:**
Suggested hydration schedule:

- Furosemide 40mg orally
- 1 litre 0.9% Sodium Chloride + 20 mmol KCl + 1g MgSO₄ IV over 60 minutes
- **Pemetrexed** in 100ml Sodium Chloride 0.9% over 10 minutes
- 30 minutes after pemetrexed:
  - **Cisplatin** in 1 litre Sodium Chloride 0.9% IV over 2 hours
  - 1 litre Sodium Chloride 0.9% + 40 mmol KCl + 1g MgSO₄ IV over 2 hours
- Then **either** 500ml Sodium Chloride 0.9% IV over 60 minutes **or** 500ml drinking water

Encourage oral hydration during treatment; for instance drink a glass of water every hour during treatment, and **at least a further 2 litres over the 24 hours following treatment**.

Weight should be recorded prior to and at the end of cisplatin treatment, and a strict fluid balance chart should be maintained. An average urine output of at least 100ml/hr must be maintained throughout treatment, and cisplatin infusion should not be commenced unless this urine output is achieved. For low urine...
output consider increasing the pre-hydration and diuretic regimen. Consider adding diuretics in weight-gain of 1.5 kg, or symptoms of fluid overload.

Aluminium containing equipment should not be used during preparation and administration of cisplatin.

Hypersensitivity reactions may occur, such as flushing, rash with or without pruritus, chest tightness, back pain, dyspnoea and fever or chills, usually during the first and second infusions and within a few minutes following the start of the infusion; the infusion should be slowed down or interrupted and the necessary supportive medication should be administered.

Severe reactions such as hypotension and/or bronchospasm or generalised rash/erythema requires immediate discontinuation. Availability of resuscitation equipment must be ensured as a standard precaution.

**Frequency:**
Day 1, every 21 days, for up to 6 cycles

**Pre-medication:**
Oral dexamethasone 4mg BD for 3 days, starting the day prior to chemotherapy (to reduce incidence / severity of skin reactions as well as anti-emetic role).

In exceptional circumstances when dexamethasone pre-medication has been omitted the day before treatment, this can be replaced with dexamethasone 8mg IV administered one hour before treatment.

**Anti-emetics:**
High emetogenicity
Follow Local Anti-emetic Policy

**Supportive medication:**
Folic acid 400micrograms orally once a day starting at least 5 days before first treatment and continuing until 3 weeks after the last pemetrexed dose.

Vitamin B₁₂ (hydroxocobalamin) 1000micrograms by IM injection, start the week before first treatment, then once every 9 weeks (can be given on same day as pemetrexed) until 3 weeks after last pemetrexed dose.

Paracetamol / Chlorphenamine/Hydrocortisone can be given for administration-related reactions such as chills/fever.

Mouthcare as per local policy.
Extravasation: Non-vesicants

Regular investigations:
- Prior to Cycle 1:
  - FBC: Day 1 (within 14 days)
  - LFTs: Day 1 (within 14 days)
  - U&Es: Day 1 (within 14 days)
  - Ca & Mg: Day 1 (within 14 days)
  - CT scan: Baseline
  - EDTA: See comments
  - Audiogram: If clinically indicated

Comments:
GFR should be calculated using the Cockcroft & Gault formula; if the calculated GFR <60 or >120ml/min measure EDTA clearance before prescribing. Monitor trends in serum creatinine between treatments, if >25% from baseline value re-calculate GFR using the Cockcroft & Gault formula.

Prior to Day 1 (all cycles):
- FBC: Day 1 (within 72 hours)
- LFTs: Day 1 (within 72 hours)
- U&Es: Day 1 (within 72 hours)
- Imaging: After 3 cycles

Toxicities:
- Myelosuppression, skin rash, alopecia (mild), mucositis, diarrhoea, neurotoxicity (including ototoxicity), nephrotoxicity, ovarian failure/infertility, nausea/vomiting.

**DOSE MODIFICATIONS**

**Haematological Toxicity**

<table>
<thead>
<tr>
<th>Neutrophils (x 10^9/L)</th>
<th>Platelets (x 10^9/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 1.5 &amp; ≥ 100</td>
<td></td>
<td>100% dose</td>
</tr>
<tr>
<td>≤ 1.5 &amp;/or ≤ 100</td>
<td></td>
<td>Delay for 1 week. Repeat FBC, if recovered to above these levels give 100% dose. For &gt;1 delay, a 25% dose reduction of both cisplatin and pemetrexed may be considered – discuss with the Consultant.</td>
</tr>
</tbody>
</table>

Disclaimer: The Joint Delivery Chemotherapy Nurse/Oncology Pharmacist Group is a sub-group of the Medicines & Chemotherapy Steering Group (MCSG) working within the London Cancer Alliance Integrated Cancer System (LCA). The output of the LCA MCSG includes documentation that can be adopted by healthcare organisations at their discretion. It is the responsibility of each individual organisation to ensure that appropriate governance and safety clearance procedures within their own clinical service have been followed prior to implementation of any such pieces of work. LCA assume no responsibility for this process within individual organisations, and no responsibility for the clinical management of individual patients or patient groups. Any clinical queries regarding individual patients or documentation should be directed to the relevant clinical team within the most appropriate healthcare organisation.
©LCA Copyright 2014
Non-haematological Toxicities

Renal Impairment

<table>
<thead>
<tr>
<th>Creatinine Clearance (ml/min)</th>
<th>Pemetrexed Dose</th>
<th>Cisplatin Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 45</td>
<td>Give 100% dose</td>
<td></td>
</tr>
<tr>
<td>&lt; 45</td>
<td>Not recommended – discuss with consultant</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Creatinine Clearance (ml/min)</th>
<th>Cisplatin Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 60</td>
<td>Give 100% dose</td>
</tr>
<tr>
<td>&lt; 60</td>
<td>Contra-indicated - consider carboplatin</td>
</tr>
</tbody>
</table>

Hepatic Impairment

<table>
<thead>
<tr>
<th>Bilirubin</th>
<th>ALP, ALT, AST</th>
<th>Pemetrexed Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤1.5 x ULN</td>
<td>≤3 x ULN</td>
<td>100% dose</td>
</tr>
<tr>
<td>≤5 x ULN if liver involvement</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

No information is available on dose reduction for pemetrexed in more severe hepatic impairment - discuss with consultant.

Dose modifications for other toxicities as appropriate

Neurotoxicity

<table>
<thead>
<tr>
<th>Neurotoxicity</th>
<th>Pemetrexed Dose</th>
<th>Cisplatin Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 2</td>
<td>Give 100% dose</td>
<td>Give 50% dose or consider switching to carboplatin</td>
</tr>
<tr>
<td>Grade 3 or 4</td>
<td>Discontinue</td>
<td>Discontinue</td>
</tr>
</tbody>
</table>

Other toxicities

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Pemetrexed Dose</th>
<th>Cisplatin Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any grade 2 toxicity</td>
<td>Give 100% dose</td>
<td>Give 100% dose</td>
</tr>
<tr>
<td>Any grade 3 or 4 toxicities (except mucositis)</td>
<td>Give 75% of previous dose</td>
<td>Give 75% of previous dose</td>
</tr>
<tr>
<td>Diarrhoea (any grade) requiring hospitalisation</td>
<td>Give 75% of previous dose</td>
<td>Give 75% of previous dose</td>
</tr>
<tr>
<td>Grade 3 or 4 mucositis</td>
<td>Give 50% of previous dose</td>
<td>Give 100% of previous dose Grade 4 mucositis give 75% of previous dose</td>
</tr>
<tr>
<td>Grade 3 or 4 mucositis</td>
<td>Give 50% of previous dose</td>
<td>Give 100% of previous dose</td>
</tr>
</tbody>
</table>

Version: 1.0 Supersedes: all other versions
Approved by LCA Lung Pathway Chemotherapy Lead: Dr Rohit Lal
Reason for Update: LCA protocol development
Approved by LCA Joint Delivery Subgroup Co-Chairs: Pauline McCalla & Rebecca Johl
Prepared by: Lisa Yuen
Approved by LCA Medicines & Chemotherapy Steering Group Chair: Jamie Ferguson
Second check by: Laura Cameron
Date prepared: November 2014
Review Date: November 2016

Disclaimer: The Joint Delivery Chemotherapy Nurse/Oncology Pharmacist Group is a sub-group of the Medicines & Chemotherapy Steering Group (MCSG) working within the London Cancer Alliance Integrated Cancer System (LCA). The output of the LCA MCSG includes documentation that can be adopted by healthcare organisations at their discretion. It is the responsibility of each individual organisation to ensure that appropriate governance and safety clearance procedures within their own clinical service have been followed prior to implementation of any such pieces of work. LCA assume no responsibility for this process within individual organisations, and no responsibility for the clinical management of individual patients or patient groups. Any clinical queries regarding individual patients or documentation should be directed to the relevant clinical team within the most appropriate healthcare organisation.
©LCA Copyright 2014
If patient suffers any Grade 3 or 4 toxicity after 2 dose reductions, treatment must be reviewed by Consultant.

Location of regimen: Day case setting delivery

Comments: Electrolyte disturbances – Cisplatin
Disturbances in electrolytes can be a long term manifestation due to the cisplatin induced renal tubular dysfunction. Check electrolytes - additional supplementation of magnesium, calcium or potassium may be required.
Women of childbearing potential must use effective contraception during treatment.
Sexually mature males are advised not to father a child during the treatment, and up to 6 months thereafter. If appropriate, male patients should be advised to seek counselling on sperm storage before starting treatment.

Drug interactions: Phenytoin, Carbamazepine
Nephrotoxic drugs, Ototoxic drugs
Non-steroidal anti-inflammatory drugs should be avoided from 5 days before each dose of pemetrexed until 2 days after each dose.
Live vaccines
Concomitant yellow fever vaccine is contra-indicated
Increased monitoring of INR levels is required with anticoagulants